Showing results (691-700 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|December 15, 2012
Sonic hedgehog antagonists induce cell death in acute myeloid leukemia cells with the presence of lipopolysaccharides, tumor necrosis factor-α, or interferonsFrank Leigh Lu, Ching-Chia Yu, Huei-Hsuan Chiu, et al.
Investigational New Drugs|December 18, 2012
Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trialsMitesh J Borad, Arundhati D Soman, Martin Benjamin, et al.
Investigational New Drugs|December 20, 2012
Potential factors correlating to the PMDA's decision to waive Japanese Phase 2 and 3 studies for oncology drugs New Drug Application in JapanKeitaro Nakajima, Koji Chiba, Hisao Tsubamoto, et al.
Investigational New Drugs|May 31, 2012
Predictive factors for response to treatment in patients with advanced renal cell carcinomaCarolina Muriel López, Emilio Esteban, Aurora Astudillo, et al.
Investigational New Drugs|September 13, 2013
Nanoparticulate paclitaxel demonstrates antitumor activity in PC3 and Ace-1 aggressive prostate cancer cell linesSandra M Axiak-Bechtel, Senthil R Kumar, Kristin K Dank, et al.
Investigational New Drugs|October 12, 2013
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumorsDustin A Deming, Jacob Ninan, Howard H Bailey, et al.
Investigational New Drugs|August 2, 2013
Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 studyPatricia M LoRusso, Smitha Krishnamurthi, Hagop Youssoufian, et al.
Investigational New Drugs|August 6, 2013
Role of IL-8 induced angiogenesis in uveal melanomaLaura Lattanzio, Federica Tonissi, Ilaria Torta, et al.
Investigational New Drugs|June 4, 2013
Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapyAnnabelle Chow, Amy Wong, Giulio Francia, et al.
Investigational New Drugs|April 24, 2013
HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancerGuru Sonpavde, Mingjun Wang, Leif E Peterson, et al.
Pageof 372